Published in J Transl Med on May 01, 2013
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell (2015) 2.12
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol (2015) 0.93
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody. J Biol Chem (2015) 0.87
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology (2015) 0.85
Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells. Immune Netw (2015) 0.81
Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care (Basel) (2016) 0.80
Ctla-4 gene polymorphism in +49 a/g position: a case control study on patients with oral lichen planus. J Int Oral Health (2014) 0.80
Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Cancer Immunol Immunother (2015) 0.78
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology (2015) 0.77
Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget (2016) 0.77
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther (2016) 0.75
The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. Vaccines (Basel) (2016) 0.75
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Front Immunol (2017) 0.75
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncoimmunology (2016) 0.75
Hypophysitis: Evaluation and Management. Clin Diabetes Endocrinol (2016) 0.75
CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunol Immunother (2017) 0.75
Restoring microenvironmental redox and pH homeostasis inhibits neoplastic cell growth and migration: therapeutic efficacy of esomeprazole plus sulfasalazine on 3-MCA-induced sarcoma. Oncotarget (2017) 0.75
Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. Intern Med (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 6.94
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 5.47
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
Molecular basis of T cell inactivation by CTLA-4. Science (1998) 3.00
A molecular perspective of CTLA-4 function. Annu Rev Immunol (2006) 2.71
Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A (2004) 2.50
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist (2007) 1.93
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol (1999) 1.66
CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol (2008) 1.60
Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol (2003) 1.54
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer (2005) 1.38
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol (2009) 1.37
Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood (2002) 1.08
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother (2012) 1.06
Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol (1999) 1.05
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood (2002) 1.02
Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol (2001) 1.00
New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets (2010) 1.00
CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol (2010) 0.98
The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma. Cancer Immunol Immunother (2001) 0.98
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood (2011) 0.97
Melanoma drug wins US approval. Nature (2011) 0.97
Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival. PLoS One (2011) 0.94
Expression of CTLA-4 by human monocytes. Scand J Immunol (2002) 0.92
The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod (1999) 0.92
Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One (2009) 0.89
CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. Cancer Immunol Immunother (2005) 0.86
Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res (1997) 0.82
CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. Br J Haematol (2007) 0.81
Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr Opin Mol Ther (2007) 0.80
Differential effect of human and mouse beta 2-microglobulin on the induction and the antigenic profile of endogenous HLA-A and -B antigens synthesized by beta 2-microglobulin gene-null FO-1 melanoma cells. Cancer Res (1993) 0.79
A human genome diversity cell line panel. Science (2002) 14.11
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2007) 3.38
Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc Natl Acad Sci U S A (2004) 3.05
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica (2007) 2.30
The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact (2011) 2.15
NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood (2005) 2.15
What is a natural killer cell? Nat Immunol (2002) 2.11
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
A randomized, placebo-controlled, preoperative trial of allopurinol in subjects with colorectal adenoma. Cancer Prev Res (Phila) (2012) 2.02
Predictors of symptomatic lymphocele after lymph node excision and radical prostatectomy. Urology (2009) 1.96
Surface NK receptors and their ligands on tumor cells. Semin Immunol (2006) 1.92
Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol (2007) 1.87
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol (2007) 1.86
A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol (2012) 1.79
Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev (2006) 1.71
A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis (2007) 1.68
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer (2008) 1.66
CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood (2010) 1.63
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer (2008) 1.56
Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood (2010) 1.56
The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol (2003) 1.55
Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur J Immunol (2004) 1.53
Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res (2005) 1.49
Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol (2009) 1.45
Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol (2012) 1.45
A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. Cell Cycle (2008) 1.45
Improving erectile function by silencing phosphodiesterase-5. J Urol (2005) 1.43
CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol (2004) 1.40
Amplification of MET in a Patient with Malignant Pleural Mesothelioma. J Thorac Oncol (2015) 1.38
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer (2005) 1.38
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol (2009) 1.37
Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. Int Immunol (2008) 1.36
Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol (2003) 1.36
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.34
De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2'-deoxycytidine. Oncogene (2005) 1.32
RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol (2002) 1.32
Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood (2010) 1.32
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One (2009) 1.30
Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci U S A (2010) 1.30
Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood (2004) 1.29
HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A (2003) 1.27
Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica (2008) 1.23
Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol (2002) 1.23
Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat Immunol (2006) 1.23
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res (2012) 1.22
Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J (2001) 1.21
Uveal melanoma. Cancer Treat Rev (2012) 1.20
Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood (2009) 1.19
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother (2011) 1.19
Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J (2005) 1.19
Origin, phenotype and function of human natural killer cells in pregnancy. Trends Immunol (2011) 1.18
Efficient generation of transgenic rats through the male germline using lentiviral transduction and transplantation of spermatogonial stem cells. J Androl (2006) 1.17
Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res (2004) 1.15
Analysis of natural killer cells isolated from human decidua: Evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function. Blood (2006) 1.14
Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res (2009) 1.13
Human natural killer cells: their origin, receptors and function. Eur J Immunol (2002) 1.13
NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol (2006) 1.13
Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett (2005) 1.12
Treatment of type 1 diabetes with adipose tissue-derived stem cells expressing pancreatic duodenal homeobox 1. Stem Cells Dev (2009) 1.12
PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol (2005) 1.11
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem (2012) 1.11
Seasonal changes in mortality rates from main causes of death in Japan (1970--1999). Eur J Epidemiol (2004) 1.11
p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer (2005) 1.10
Extracellular DNA in biofilms. Int J Artif Organs (2011) 1.10
CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci U S A (2011) 1.09
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 1.09
CpG sites preferentially methylated by Dnmt3a in vivo. J Biol Chem (2006) 1.09
Recruitment of a host's osteoprogenitor cells using exogenous mesenchymal stem cells seeded on porous ceramic. Tissue Eng Part A (2009) 1.09
Genetic engineering of human embryonic stem cells with lentiviral vectors. Stem Cells Dev (2005) 1.09
NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends Immunol (2003) 1.09
Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood (2002) 1.08
Dynamic DNA methylation and histone modifications contribute to lentiviral transgene silencing in murine embryonic carcinoma cells. J Virol (2005) 1.08
Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol (2014) 1.08